CPHI · NYSE · Healthcare · Drug Manufacturers Specialty and Generic
Next earnings: November 11, 2026
$0.73-3.2%Sep 28 close
China Pharma Holdings, Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $948.3K | $1M | -7.55% |
| Profit | -$1.5M | -$528.4K | -175.97% |
| Profit per share | -$0.04 | -$0.16 | +75.00% |
| Free Cash Flow | $151.5K | $279.2K | -45.73% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company’s wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from China Pharma Holdings, Inc.’s Item 2.02 8-K filed March 31, 2017; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
China Pharma Holdings, Inc. has no earnings call transcript available.